98%
921
2 minutes
20
Objective: Brain arteriovenous malformations (AVMs) in patients with hereditary hemorrhagic telangiectasia (HHT) present different characteristics from sporadic AVMs, and they have lower initial bleeding rates. Conservative management is usually preferred for the treatment of these lesions. In this case study, we present the largest series of HHT patients treated with stereotactic radiosurgery to date.
Methods: We identified eight patients with HHT and 14 AVMs. We retrospectively collected clinical, radiographic, and treatment characteristics of the patients and each AVM.
Results: Most patients in our sample presented with small AVMs. The median volume of these AVMs was 0.22 cm (IQR 0.08-0.59). Three out of eight patients presented with initial intracerebral hemorrhage (ICH). The majority of lesions had low (12/14) Spetzler-Martin grades (I-II). Median maximum and margin doses used for treatment were 36.2 (IQR 35.25-44.4) and 20 (IQR 18-22.5) Gy, respectively. The overall obliteration rate after SRS was 11/14, and the median time to obliteration across all 11 obliterated AVMs was 35.83 months (IQR, 17-39.99). Neurological status was favorable with all patients having a mRS of 0 or 1 at the last follow-up. Symptomatic radiation-induced changes (RIC) after SRS were low (7.1%), and there were no permanent RIC.
Conclusions: Patients with HHT who present with multiple brain AVMs are generally well served by SRS. Obliteration can be achieved in the majority of HHT patients and with a low complication rate. In the current study, initial hemorrhage rates prior to SRS were noticeable which supports the decision to treat these AVMs. Future studies are needed to better address the role of SRS for HHT patients harboring ruptured and unruptured AVMs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794397 | PMC |
http://dx.doi.org/10.1007/s00701-024-05923-4 | DOI Listing |
Orphanet J Rare Dis
August 2025
Toronto HHT Centre, Keenan Research Centre in the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada.
Background: There is increasing evidence of health outcome disparities due to inequitable healthcare. These inequities are likely compounded in rare disease care and research. We aimed to identify disparities in access to clinical care and research for patients with hereditary hemorrhagic telangiectasia (HHT) in North America.
View Article and Find Full Text PDFCureus
July 2025
Pulmonary and Critical Care Medicine, Christian Medical College Vellore, Vellore, IND.
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber syndrome, is a rare autosomal dominant disorder characterized by mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs). We report a case of a 58-year-old female who presented with acute dyspnea and right-sided pleuritic chest pain. Her history included recurrent epistaxis since childhood and a positive family history of similar symptoms.
View Article and Find Full Text PDFHepatol Res
August 2025
Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Aim: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that can cause vascular malformations in multiple organs, including the liver. Although liver involvement typically remains asymptomatic until adulthood, severe cases can progress to high-output cardiac failure (HOCF). Although liver transplantation (LT) is a well-established curative option for adult patients with HHT, pediatric data are limited.
View Article and Find Full Text PDFLaryngoscope
August 2025
Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel.
Objective: A validated and practical grading system for endoscopic findings is crucial for both clinical care and research when evaluating patients with Hereditary Hemorrhagic Telangiectasia (HHT) who experience epistaxis and nasal complaints. This study aimed to validate a novel, simplified nasal endoscopy grading system in HHT patients.
Methods: The study was conducted at a tertiary referral center for HHT patients.
Hematology
December 2025
Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Background: The bone marrow (BM) microenvironment in acute myeloid leukemia (AML) shields leukemic cells from chemotherapy, fostering disease recurrence and progression.
Objectives: This study investigated the impact of eukaryotic initiation factor 4E (eIF4E) in AML progression and chemosensitivity, highlighting stroma-dependent chemoprotection mechanisms to develop potential microenvironment-directed therapies.
Methods: The GEO dataset was analyzed for the relationship between eIF4E mRNA expression and clinical characteristics in AML patients.